Stem cells are used in cell therapy for degenerative disorders. The main advantage of stem cells is that they can replenish their numbers for long periods through cell division and, produce a progeny that can differentiate into multiple cell lineages with specific functions. CD133 is a member of a novel family of cell surface glycoproteins. The expression of human CD133 (AC133 antigen) was originally described in the hematopoietic CD34+ stem cells, but now it becomes more and more evident that CD133 is a marker of stem and progenitor cell populations originating from various tissues and organs. The main objective of this chapter is to describe the potential sources of CD133+ stem cells that harbor the ability to engraft, proliferate and differentiate into functional cells. The characterization of such CD133+ stem cells unlocks new opportunities in the treatment of degenerative diseases such as Duchenne muscular dystrophy.

CD133+ Cells for the Treatment of Degenerative Diseases : update and perspectives / M. Meregalli, A. Farini, M.L.C. Belicchi, Y. Torrente (ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY). - In: Prominin-1 (CD133): new insights on stem & cancer stem cell biology / [a cura di] D. Corbeil. - New York : Springer, 2013. - ISBN 978-1-4614-5893-7. - pp. 229-243

CD133+ Cells for the Treatment of Degenerative Diseases : update and perspectives

M. Meregalli;A. Farini;M.L.C. Belicchi;Y. Torrente
2013

Abstract

Stem cells are used in cell therapy for degenerative disorders. The main advantage of stem cells is that they can replenish their numbers for long periods through cell division and, produce a progeny that can differentiate into multiple cell lineages with specific functions. CD133 is a member of a novel family of cell surface glycoproteins. The expression of human CD133 (AC133 antigen) was originally described in the hematopoietic CD34+ stem cells, but now it becomes more and more evident that CD133 is a marker of stem and progenitor cell populations originating from various tissues and organs. The main objective of this chapter is to describe the potential sources of CD133+ stem cells that harbor the ability to engraft, proliferate and differentiate into functional cells. The characterization of such CD133+ stem cells unlocks new opportunities in the treatment of degenerative diseases such as Duchenne muscular dystrophy.
CD133+ stem cell ; degenerative disease ; heterogeneity ; muscular dystrophy ; therapeutic application
Settore MED/26 - Neurologia
Book Part (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/213975
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 2
social impact